Physician profile
Bayan MD Mesmar
NPI 1306192976
$1,612.43
in general payments reported to CMS, 2019-2025
18 companies · $327 in 2025
The $327 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $889 · 2020: $274 · 2022: $12.41 · 2024: $110 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $436.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $362.36 | 2019-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $307.10 | 2019-2024 | |
| Lilly USA, LLC | $240.74 | 2019-2025 | Zepbound |
| Astrazeneca Pharmaceuticals LP | $129.32 | 2019 | |
| Medtronic, INC. | $118.34 | 2025 | Minimed 780g |
| Amgen INC. | $77.33 | 2019-2020 | |
| Corcept Therapeutics | $57.96 | 2019 | |
| Valeritas, INC. | $51.38 | 2019 | |
| Shire North American Group INC | $44.32 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.58 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $39.89 | 2019 | |
| Abbott Laboratories | $24.05 | 2025 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $23.37 | 2019 | |
| Xeris Pharmaceuticals, INC. | $21.70 | 2020 | |
| Abbvie INC. | $20.52 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $19.06 | 2020 | |
| Becton, Dickinson and Company | $17.84 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bayan Mesmar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.